Related Experiment Video

Updated: Oct 9, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

729

miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin's Lymphoma: Moving towards an RNA-Guided Precision Medicine

Mara Fernandes1,2,3, Herlander Marques4,5,6,7, Ana Luísa Teixeira1,8

  • 1Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal.

Cancers
|December 24, 2021
PubMed

Insights

MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) show therapeutic potential in lymphoma by targeting multiple genes. Delivery systems and clinical trials are advancing these novel treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biotechnology

Background:

  • MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) play critical roles in lymphoma development and progression.
  • These non-coding RNAs can act as either tumor suppressors or oncogenes, making them attractive therapeutic targets.

Purpose of the Study:

  • To review the fundamentals of miRNA- and lncRNA-based therapeutics for lymphoma.
  • To discuss delivery systems investigated for lymphoma treatment in vitro and in vivo.
  • To summarize ongoing clinical trials involving these novel therapeutics.

Main Methods:

  • Literature review of preclinical and clinical studies on miRNA- and lncRNA-based lymphoma therapies.
  • Analysis of different delivery systems and their efficacy.
  • Examination of current clinical trial data.

Main Results:

  • miRNAs and lncRNAs offer a promising approach to modulate multiple targets in lymphoma.
  • Challenges in clinical application include delivery, off-target effects, and safety, which are being addressed by chemical modifications and targeted delivery.
  • These therapies are being explored as monotherapies and in combination with standard treatments to enhance efficacy and overcome resistance.

Conclusions:

  • miRNA- and lncRNA-based therapies represent a significant advancement in lymphoma treatment strategies.
  • Ongoing research and clinical trials are crucial for overcoming current limitations and realizing the full therapeutic potential.
  • Further development of delivery systems and combination strategies is key to improving patient outcomes in lymphoma.
Keywords:
Non-Hodgkin’s lymphomalncRNAslymphomamiRNAsncRNA-based therapy

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.8K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.6K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.4K